Simpson Thacher represented the initial purchasers, led by J.P. Morgan Securities LLC, in connection with a Rule 144A/Regulation S offering by Endo Luxembourg Finance Company I S.à r.l. and Endo U.S. Inc., subsidiaries of Endo International plc (“Endo International”), of $1.295 billion aggregate principal amount of 6.125% Senior Secured Notes due 2029.
The Firm also represented JPMorgan Chase Bank, N.A., as lead arranger and administrative agent, and the other lenders thereto in connection with an amendment and restatement of Endo International’s credit agreement to, among other things, refinance its existing term loan facility with a new tranche of term loans maturing March, 2028 and extend the maturity of a majority of its revolving credit facility from March 2024 to March 2026 (other than with respect to the revolving commitments of non-extending lenders).
The net proceeds of the notes offering, together with the net proceeds of the new term loan facility and cash on hand, were used to fully repay Endo International’s existing term loan facility.
Endo International is a specialty pharmaceutical company committed to helping everyone they serve live their best life through the delivery of high-quality, life-enhancing therapies.
The Simpson Thacher team included Art Robinson, Marisa Stavenas, John O’Connell, Jieun Lim and Taylor Wettach (Capital Markets); Bill Sheehan, Robert Meyer, Kalyan Venkatraj, Chris Zheng and Humberto Romero Carrillo (Credit); Jonathan Pall and Soogy Lee (Collateral); Jon Cantor and Ed Grais (Tax); Vanessa Burrows (Healthcare); Genevieve Dorment, Kate Mirino and Bobbie Burrows (Intellectual Property); Jennie Getsin (FINRA/Blue Sky); Jeanne Annarumma and Alisa Tschorke (Executive Compensation and Benefits); and Timothy Mulvihill (Environmental).